SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
INHL - Inhale Therapeutics - Pulmonary Insulin!
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
225 29 0 INHL
Emcee:  Rick Costantino Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
225update from Morgan January 10, 2007 Nektar Therapeutics Time to Walk the Walk Cdeeno-1/11/2007
224great thanks. this blfrproducts.com are launched too, I was wondering if anyone longtermholdings-12/13/2006
223Launched, available, mediocre/subdued response and interest, many competitors codeeno-12/11/2006
222any word on how the launch went? Is this product available to the public?longtermholdings-12/10/2006
221June 14, 2006 Nektar Therapeutics Mixed Feedback on Exubera at ADA Morgan Stanledeeno-6/14/2006
220Thanks for your input.david nordic-10/16/2005
219your righ,t a billion or so a year, but after all the dilution, pfizer getting tdeeno-10/13/2005
218We will see. Exubera is not going to be that small either. Im long and fully invdavid nordic-10/13/2005
217not going to be as big a market as the bulls think.deeno-10/9/2005
216What are the thoughts on Exubera being approved (FDA / Europe)? The 7/2 advisorydavid nordic-10/7/2005
215[Antibody Response to Inhaled Insulin in Patients with Type 1 or Type 2 Diabetestuck-3/3/2005
214long time no hear from the other 62 people that have this bookmarked. Though I deeno-2/23/2005
213Merrill NKTR; $10.00; C-1-9 12-Month Price Objective: $28.00 (10-Mar-2004) EPS deeno-8/5/2004
212Welcome, jamescmercer [Sign Out] Money Manager - My Yahoo! View - Customize Findeeno-8/5/2004
211response EPS (Dec): 2003A -$1.34; 2004E -$0.97; 2005E -$0.77 GAAP EPS (Dec): 20deeno-6/10/2004
210more comments NKTR; EPS (Dec): 2003A -$1.34; 2004E -$0.97; 2005E -$0.77 GAAP deeno-6/7/2004
209Merrill comments. • NKTR is scheduled to report Q3/03 (ended September) financideeno-10/22/2003
208Anyone know whats going on? EOMdeeno-9/10/2003
207From ADA meeting: >>Efficacy and Safety of Inhaled Insulin (Exubera[reg]tuck-6/14/2003
206>>SAN CARLOS, Calif.--(BUSINESS WIRE)--Nov. 21, 2002--Inhale Therapeutic Stuck-11/21/2002
205SAN CARLOS, Calif. and SLOUGH, England--(BUSINESS WIRE)--Oct. 18, 2002--Inhale Tnigel bates-10/18/2002
204Reuters Company News Roche wins FDA approval for hepatitis C drug Wednesday OctMiljenko Zuanic-10/17/2002
203Exubera as effective as injected insulin in phase III, but lung function issues michael_f_murphy-6/18/2002
202Inhale Reports on Phase III Exubera Inhaled Insulin Data that Show Comparable GlSemiBull-6/17/2002
201The additional testing might well affect competitive products that are inhaled, tuck-12/19/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News